Background
==========

Tremelimumab is a fully human monoclonal antibody that binds to CTLA-4 expressed on the surface of activated T lymphocytes and results in inhibition of B7-CTLA-4-mediated down regulation of T cell activation. Both transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) have been shown to induce a peripheral immune response which may enhance the effect of anti-CTLA4 treatment in patients with advanced HCC.

Methods
=======

Patients with HCC (Childs Pugh A/B7; Barcelona Clinic Liver Cancer Stage C; ECOG 0/1; previously progressed on Sorafenib) are being enrolled in a pilot study of Tremelimumab at 2 dose levels (DL1 and DL2) until disease progression (irRECIST). Subtotal TACE or RFA is performed during study week 6 with DLT evaluation period encompassing first 8 weeks of study. Tumor tissue is collected for analysis at baseline on all patients with optional on-treatment tumor biopsies performed at the time of the radiologic procedure.

Results
=======

11 pts have been treated so far, 6 pts at DL1 and 5 pts at DL2; M:F 9:2; Median age = 54(range 42-75); Cirrhosis present in 7pts. Hepatitis B/C/neg: 3/6/2. 4 pts received TACE, 7 underwent RFA during week 6 of Tremelimumab therapy. Tumor tissue is being collected for analysis at baseline in all patients. Once DL1 was established as safe and feasible on-treatment tumor biopsies are being performed at the time of the radiologic procedure (Day 36 +/- 96hrs) on all patients. So far 2 of 5 patients treated at DL2 have shown extensive immune cell infiltration on tumor biopsies after 6 weeks of Tremelimumab. More in depth analysis are currently being conducted and will be presented together with safety data.

Conclusions
===========

Tremelimumab in combination with TACE or RFA in patients with advanced HCC is feasible. Preliminary pathology data will be presented regarding all post-treatment tumor biopsies.
